Germany, France, Spain suspend AstraZeneca COVID-19 jabs amid blood-clot concerns

  • Germany, Italy, France and Spain joined the ranks of European countries that have temporarily halted use of AstraZeneca's (NASDAQ:AZN) COVID-19 shots after several countries reported possible serious side-effects.
  • This move is another blow to the continent's sluggish vaccination rollout and threatens the credibility of jab itself.
  • German Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.
  • 'This is a professional decision, not a political one," Spahn said, adding he was following a recommendation of the Paul Ehrlich Institute, Germany's vaccine regulator.
  • Seven cases of blood clotting were reported in Germany following the administration of 1.6M doses in the country.
  • France and Italy suspended the vaccine's use pending an assessment by EMA.
  • 'The decision taken, in conformity also with our European policy, is to suspend, out of precaution, vaccination with the AZ shot, hoping that we can resume quickly if the EMA's guidance allows," French President Emmanuel Macron said.
  • 'The EMA will meet soon to clarify any doubts so that the AstraZeneca vaccine can be resumed safely in the vaccination campaign as soon as possible," said Gianni Rezza, Director General of Prevention at Italy's Ministry of Health.
  • AstraZeneca said earlier it had conducted a review covering more than 17M people vaccinated in the EU and the UK which had shown no evidence of an increased risk of blood clots.

    Investors in Astrazeneca can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the English market. Per share the analysts are expecting a dividend of 284 GBp per share. Thus the dividend yield equals 3.99 percent. The average dividend yield of the pharmaceutical companies equals a low 0.38 percent.

    Historical dividend returns Astrazeneca

    Over the current book year the total revenue from the company in Cambridge will be 31.29 billion GBp (consensus estimates). This is rather significant more than 2020's revenue of 26.62 billion GBp.

    Historical revenues and results Astrazeneca plus estimates 2020

    fundamenteel onderzoek

    The analysts expect for 2021 a net profit of 6.87 billion GBp. For this year the consensus of the result per share is a profit of 509 GBp. Based on this the price/earnings-ratio is 13.97.

    Latest estimates around 9017 GBp

    The most recent recommendations for the pharmaceutical company are from Deutsche Bank , Jefferies & Co. and UBS .

    Based on the current number of shares Astrazeneca 's market capitalization equals 9329.3 billion GBp. The Astrazeneca stock was the past 12 months quite unstable. Since last March the stock is 6 percent higher. This year the stock price moved between 6598 and 10120 GBp.

    Historical stock prices Astrazeneca past 10 years

    stock price astrazeneca

    Click here for dividend Astrazeneca. On Friday the stock closed at 7110 GBp.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    AstraZeneca signs deal to supply Canada 100k doses of COVID antibody therapy Evusheld
    Analysts expect revenue increase Astrazeneca
    AstraZeneca teams up with Scorpion Therapeutics to develop cancer treatments
    AstraZeneca, Oxford start work on Omicron-specific COVID vaccine
    Denmark to continuing banning J&J AstraZeneca vaccines
    AstraZeneca, Junshi Bio collaborate to commercialize toripalimab in China
    AstraZeneca's COVID-19 vaccine wins Australian nod
    Sector news
    Analysts expect over 2023 revenue increase UCB
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Analysts: this year best year ever for Carl Zeiss Meditec
    Sanofi-Aventis now in top highest dividend yields in France
    Extreme dividend yield Novartis
    Pfizer now in top highest dividend yields in America
    2023 record year for Johnson & Johnson
    National news
    Analysts expect over 2023 revenue increase Drax Group PLC, quite high dividend
    BHP maintains iron ore production guidance, cuts outlook for copper and nickel
    BHP maintains iron ore production guidance, cuts outlook for copper and nickel
    Rio Tinto starts iron ore deliveries from $3B Australia mining project
    Rio takes control of Australia partnership with Russia's Rusal
    BP seeks to sell shut-down North Sea oilfield
    BP to break from Rosneft, will exit its nearly 20 % stake
    Press news
    Cold Plasma Market To Reach USD 8.6 Billion By 2032, Report By DataHorizzon Research
    Physical Identity and Access Management Market To Reach USD 3.3 Billion By 2032 | DataHorizzon Research
    Pain Management Therapeutics Market To Reach USD 115.1 Billion By 2032 | DataHorizzon Research
    Life Science Tools and Reagents Market To Reach USD 453.2 Billion By 2032 | DataHorizzon Research
    STEICO: Correction to the corporate news from 19 April 2024. Net profit for the period Q1 2024: € 5.9 million; previous year € 2.1 million.
    Chicory Market To Reach USD 1,561.4 Million By 2032 | DataHorizzon Research
    Steam Trap Market To Reach USD 5.2 Billion By 2032 | DataHorizzon Research
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo